A comprehensive view of non-vaccine biologics. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Health Care Sector Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

TriLink BioTechnologies to expand its mRNA manufacturing facility near San Diego, California, to meet demand from late-stage drug developers; new 32,000-square-foot facility to produce gene edited cell therapies, protein replacement therapies, vaccines

Global drug and gene delivery systems market estimated to grow to US$815.6B by 2030, have CAGR growth of 7.33% from 2023 to 2030; growth driven by nanotechnology advancements, demand for non-invasive drug delivery methods, rise in biologics development

Janssen to present updates on gene therapies for retinal diseases at ARVO 2023 Annual Meeting, including Phase 1/2 trial for X-linked retinitis pigmentosa and pooled safety data for age-related macular degeneration

Moderna partners with IBM to explore quantum computing and AI for mRNA medicine development; Moderna and IBM to use MolFormer AI foundation model to to design mRNA medicines with optimal safety and performance

Novo Nordisk and Aspect Biosystems collaborate in deal worth up to US$2.675B to develop implantable, bioprinted tissue therapeutics for diabetes and obesity, leveraging Aspect's bioprinting tech and Novo Nordisk's stem-cell expertise

Ask us about our Health Care Sector market view

Trending Chart

Interactive chart with headline count